Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 24 entries
Sorted by: Best Match Show Resources per page
Mnk Kinases in Cytokine Signaling and Regulation of Cytokine Responses.

Biomolecular concepts

Joshi S, Platanias LC.
PMID: 23710261
Biomol Concepts. 2012 Apr;3(2):127-139. doi: 10.1515/bmc-2011-0057.

The kinases Mnk1 and Mnk2 are activated downstream of the p38 MAPK and MEK/ERK signaling pathways. Extensive work over the years has shown that these kinases control phosphorylation of the eukaryotic initiation factor 4E (eIF4E) and regulate engagement of...

Cite
Joshi S, Platanias LC. Mnk Kinases in Cytokine Signaling and Regulation of Cytokine Responses. Biomol Concepts. 2012;3(2):127-139doi: 10.1515/bmc-2011-0057.
Joshi, S., & Platanias, L. C. (2012). Mnk Kinases in Cytokine Signaling and Regulation of Cytokine Responses. Biomolecular concepts, 3(2), 127-139. https://doi.org/10.1515/bmc-2011-0057
Joshi, Sonali, and Platanias, Leonidas C. "Mnk Kinases in Cytokine Signaling and Regulation of Cytokine Responses." Biomolecular concepts vol. 3,2 (2012): 127-139. doi: https://doi.org/10.1515/bmc-2011-0057
Joshi S, Platanias LC. Mnk Kinases in Cytokine Signaling and Regulation of Cytokine Responses. Biomol Concepts. 2012 Apr;3(2):127-139. doi: 10.1515/bmc-2011-0057. PMID: 23710261; PMCID: PMC3662029.
Copy Download .nbib Format: NLM
Abnormalities in Th17 T cells in aplastic anemia.

Blood

Platanias LC.
PMID: 21088141
Blood. 2010 Nov 18;116(20):4039-40. doi: 10.1182/blood-2010-09-305367.

No abstract available.

Cite
Platanias LC. Abnormalities in Th17 T cells in aplastic anemia. Blood. 2010;116(20):4039-40doi: 10.1182/blood-2010-09-305367.
Platanias, L. C. (2010). Abnormalities in Th17 T cells in aplastic anemia. Blood, 116(20), 4039-40. https://doi.org/10.1182/blood-2010-09-305367
Platanias, Leonidas C. "Abnormalities in Th17 T cells in aplastic anemia." Blood vol. 116,20 (2010): 4039-40. doi: https://doi.org/10.1182/blood-2010-09-305367
Platanias LC. Abnormalities in Th17 T cells in aplastic anemia. Blood. 2010 Nov 18;116(20):4039-40. doi: 10.1182/blood-2010-09-305367. PMID: 21088141.
Copy Download .nbib Format: NLM
Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer.

Oncotarget

Brisard D, Eckerdt F, Marsh LA, Blyth GT, Jain S, Cristofanilli M, Horiuchi D, Platanias LC.
PMID: 30647871
Oncotarget. 2018 Dec 18;9(99):37305-37318. doi: 10.18632/oncotarget.26468. eCollection 2018 Dec 18.

Treatment options for triple-negative breast cancer (TNBC) are limited due to the lack of efficient targeted therapies, frequently resulting in recurrence and metastatic disease. Accumulating evidence suggests that a small population of cancer stem-like cells (CSLCs) is responsible for...

Cite
Brisard D, Eckerdt F, Marsh LA, et al. Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer. Oncotarget. 2018;9(99):37305-37318doi: 10.18632/oncotarget.26468.
Brisard, D., Eckerdt, F., Marsh, L. A., Blyth, G. T., Jain, S., Cristofanilli, M., Horiuchi, D., & Platanias, L. C. (2018). Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer. Oncotarget, 9(99), 37305-37318. https://doi.org/10.18632/oncotarget.26468
Brisard, Daphne, et al. "Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer." Oncotarget vol. 9,99 (2018): 37305-37318. doi: https://doi.org/10.18632/oncotarget.26468
Brisard D, Eckerdt F, Marsh LA, Blyth GT, Jain S, Cristofanilli M, Horiuchi D, Platanias LC. Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer. Oncotarget. 2018 Dec 18;9(99):37305-37318. doi: 10.18632/oncotarget.26468. eCollection 2018 Dec 18. PMID: 30647871; PMCID: PMC6324664.
Copy Download .nbib Format: NLM
Can early intervention with pharmacotherapy reduce the morbidity and mortality of chronic lymphocytic leukemia?.

Expert opinion on pharmacotherapy

Ma S, Platanias LC.
PMID: 30020813
Expert Opin Pharmacother. 2018 Aug;19(11):1171-1175. doi: 10.1080/14656566.2018.1498844. Epub 2018 Jul 18.

No abstract available.

Cite
Ma S, Platanias LC. Can early intervention with pharmacotherapy reduce the morbidity and mortality of chronic lymphocytic leukemia?. Expert Opin Pharmacother. 2018;19(11):1171-1175doi: 10.1080/14656566.2018.1498844.
Ma, S., & Platanias, L. C. (2018). Can early intervention with pharmacotherapy reduce the morbidity and mortality of chronic lymphocytic leukemia?. Expert opinion on pharmacotherapy, 19(11), 1171-1175. https://doi.org/10.1080/14656566.2018.1498844
Ma, Shuo, and Platanias, Leonidas C. "Can early intervention with pharmacotherapy reduce the morbidity and mortality of chronic lymphocytic leukemia?." Expert opinion on pharmacotherapy vol. 19,11 (2018): 1171-1175. doi: https://doi.org/10.1080/14656566.2018.1498844
Ma S, Platanias LC. Can early intervention with pharmacotherapy reduce the morbidity and mortality of chronic lymphocytic leukemia?. Expert Opin Pharmacother. 2018 Aug;19(11):1171-1175. doi: 10.1080/14656566.2018.1498844. Epub 2018 Jul 18. PMID: 30020813.
Copy Download .nbib Format: NLM
Glioblastoma as an age-related neurological disorder in adults.

Neuro-oncology advances

Kim M, Ladomersky E, Mozny A, Kocherginsky M, O'Shea K, Reinstein ZZ, Zhai L, Bell A, Lauing KL, Bollu L, Rabin E, Dixit K, Kumthekar P, Platanias LC, Hou L, Zheng Y, Wu J, Zhang B, Hrachova M, Merrill SA, Mrugala MM, Prabhu VC, Horbinski C, James CD, Yamini B, Ostrom QT, Johnson MO, Reardon DA, Lukas RV, Wainwright DA.
PMID: 34647022
Neurooncol Adv. 2021 Sep 04;3(1):vdab125. doi: 10.1093/noajnl/vdab125. eCollection 2021.

BACKGROUND: Advanced age is a major risk factor for the development of many diseases including those affecting the central nervous system. Wild-type isocitrate dehydrogenase glioblastoma (IDHMETHODS: The Surveillance, Epidemiology, and End Results, The Cancer Genome Atlas, and the Chinese...

Cite
Kim M, Ladomersky E, Mozny A, et al. Glioblastoma as an age-related neurological disorder in adults. Neurooncol Adv. 2021;3(1):vdab125doi: 10.1093/noajnl/vdab125.
Kim, M., Ladomersky, E., Mozny, A., Kocherginsky, M., O'Shea, K., Reinstein, Z. Z., Zhai, L., Bell, A., Lauing, K. L., Bollu, L., Rabin, E., Dixit, K., Kumthekar, P., Platanias, L. C., Hou, L., Zheng, Y., Wu, J., Zhang, B., Hrachova, M., Merrill, S. A., Mrugala, M. M., Prabhu, V. C., Horbinski, C., James, C. D., Yamini, B., Ostrom, Q. T., Johnson, M. O., Reardon, D. A., Lukas, R. V., & Wainwright, D. A. (2021). Glioblastoma as an age-related neurological disorder in adults. Neuro-oncology advances, 3(1), vdab125. https://doi.org/10.1093/noajnl/vdab125
Kim, Miri, et al. "Glioblastoma as an age-related neurological disorder in adults." Neuro-oncology advances vol. 3,1 (2021): vdab125. doi: https://doi.org/10.1093/noajnl/vdab125
Kim M, Ladomersky E, Mozny A, Kocherginsky M, O'Shea K, Reinstein ZZ, Zhai L, Bell A, Lauing KL, Bollu L, Rabin E, Dixit K, Kumthekar P, Platanias LC, Hou L, Zheng Y, Wu J, Zhang B, Hrachova M, Merrill SA, Mrugala MM, Prabhu VC, Horbinski C, James CD, Yamini B, Ostrom QT, Johnson MO, Reardon DA, Lukas RV, Wainwright DA. Glioblastoma as an age-related neurological disorder in adults. Neurooncol Adv. 2021 Sep 04;3(1):vdab125. doi: 10.1093/noajnl/vdab125. eCollection 2021. PMID: 34647022; PMCID: PMC8500689.
Copy Download .nbib Format: NLM
Interferon maintenance for prevention of relapse in favorable risk AML?.

Leukemia & lymphoma

Small SH, Altman JK, Platanias LC.
PMID: 34477023
Leuk Lymphoma. 2021 Dec;62(12):2818-2819. doi: 10.1080/10428194.2021.1966790. Epub 2021 Sep 03.

No abstract available.

Cite
Small SH, Altman JK, Platanias LC. Interferon maintenance for prevention of relapse in favorable risk AML?. Leuk Lymphoma. 2021;62(12):2818-2819doi: 10.1080/10428194.2021.1966790.
Small, S. H., Altman, J. K., & Platanias, L. C. (2021). Interferon maintenance for prevention of relapse in favorable risk AML?. Leukemia & lymphoma, 62(12), 2818-2819. https://doi.org/10.1080/10428194.2021.1966790
Small, Sara H, et al. "Interferon maintenance for prevention of relapse in favorable risk AML?." Leukemia & lymphoma vol. 62,12 (2021): 2818-2819. doi: https://doi.org/10.1080/10428194.2021.1966790
Small SH, Altman JK, Platanias LC. Interferon maintenance for prevention of relapse in favorable risk AML?. Leuk Lymphoma. 2021 Dec;62(12):2818-2819. doi: 10.1080/10428194.2021.1966790. Epub 2021 Sep 03. PMID: 34477023.
Copy Download .nbib Format: NLM
Glioblastoma as an age-related neurological disorder in adults.

Neuro-oncology advances

Kim M, Ladomersky E, Mozny A, Kocherginsky M, O'Shea K, Reinstein ZZ, Zhai L, Bell A, Lauing KL, Bollu L, Rabin E, Dixit K, Kumthekar P, Platanias LC, Hou L, Zheng Y, Wu J, Zhang B, Hrachova M, Merrill SA, Mrugala MM, Prabhu VC, Horbinski C, James CD, Yamini B, Ostrom QT, Johnson MO, Reardon DA, Lukas RV, Wainwright DA.
PMID: 34647022
Neurooncol Adv. 2021 Sep 04;3(1):vdab125. doi: 10.1093/noajnl/vdab125. eCollection 2021.

BACKGROUND: Advanced age is a major risk factor for the development of many diseases including those affecting the central nervous system. Wild-type isocitrate dehydrogenase glioblastoma (IDHMETHODS: The Surveillance, Epidemiology, and End Results, The Cancer Genome Atlas, and the Chinese...

Cite
Kim M, Ladomersky E, Mozny A, et al. Glioblastoma as an age-related neurological disorder in adults. Neurooncol Adv. 2021;3(1):vdab125doi: 10.1093/noajnl/vdab125.
Kim, M., Ladomersky, E., Mozny, A., Kocherginsky, M., O'Shea, K., Reinstein, Z. Z., Zhai, L., Bell, A., Lauing, K. L., Bollu, L., Rabin, E., Dixit, K., Kumthekar, P., Platanias, L. C., Hou, L., Zheng, Y., Wu, J., Zhang, B., Hrachova, M., Merrill, S. A., Mrugala, M. M., Prabhu, V. C., Horbinski, C., James, C. D., Yamini, B., Ostrom, Q. T., Johnson, M. O., Reardon, D. A., Lukas, R. V., & Wainwright, D. A. (2021). Glioblastoma as an age-related neurological disorder in adults. Neuro-oncology advances, 3(1), vdab125. https://doi.org/10.1093/noajnl/vdab125
Kim, Miri, et al. "Glioblastoma as an age-related neurological disorder in adults." Neuro-oncology advances vol. 3,1 (2021): vdab125. doi: https://doi.org/10.1093/noajnl/vdab125
Kim M, Ladomersky E, Mozny A, Kocherginsky M, O'Shea K, Reinstein ZZ, Zhai L, Bell A, Lauing KL, Bollu L, Rabin E, Dixit K, Kumthekar P, Platanias LC, Hou L, Zheng Y, Wu J, Zhang B, Hrachova M, Merrill SA, Mrugala MM, Prabhu VC, Horbinski C, James CD, Yamini B, Ostrom QT, Johnson MO, Reardon DA, Lukas RV, Wainwright DA. Glioblastoma as an age-related neurological disorder in adults. Neurooncol Adv. 2021 Sep 04;3(1):vdab125. doi: 10.1093/noajnl/vdab125. eCollection 2021. PMID: 34647022; PMCID: PMC8500689.
Copy Download .nbib Format: NLM
Disclose and Manage Conflicts of Interest at Cancer Centers.

JAMA internal medicine

Jensen RA, Knudsen KE, Platanias LC.
PMID: 31904783
JAMA Intern Med. 2020 Jan 01;180(1):161. doi: 10.1001/jamainternmed.2019.5542.

No abstract available.

Cite
Jensen RA, Knudsen KE, Platanias LC. Disclose and Manage Conflicts of Interest at Cancer Centers. JAMA Intern Med. 2020;180(1):161doi: 10.1001/jamainternmed.2019.5542.
Jensen, R. A., Knudsen, K. E., & Platanias, L. C. (2020). Disclose and Manage Conflicts of Interest at Cancer Centers. JAMA internal medicine, 180(1), 161. https://doi.org/10.1001/jamainternmed.2019.5542
Jensen, Roy A, et al. "Disclose and Manage Conflicts of Interest at Cancer Centers." JAMA internal medicine vol. 180,1 (2020): 161. doi: https://doi.org/10.1001/jamainternmed.2019.5542
Jensen RA, Knudsen KE, Platanias LC. Disclose and Manage Conflicts of Interest at Cancer Centers. JAMA Intern Med. 2020 Jan 01;180(1):161. doi: 10.1001/jamainternmed.2019.5542. PMID: 31904783.
Copy Download .nbib Format: NLM
Regulation of CDX4 gene transcription by HoxA9, HoxA10, the Mll-Ell oncogene and Shp2 during leukemogenesis.

Oncogenesis

Bei L, Shah C, Wang H, Huang W, Platanias LC, Eklund EA.
PMID: 25531430
Oncogenesis. 2014 Dec 22;3:e135. doi: 10.1038/oncsis.2014.49.

Cdx and Hox proteins are homeodomain transcription factors that regulate hematopoiesis. Transcription of the HOX and CDX genes decreases during normal myelopoiesis, but is aberrantly sustained in leukemias with translocation or partial tandem duplication of the MLL1 gene. Cdx4...

Cite
Bei L, Shah C, Wang H, et al. Regulation of CDX4 gene transcription by HoxA9, HoxA10, the Mll-Ell oncogene and Shp2 during leukemogenesis. Oncogenesis. 2014;3:e135doi: 10.1038/oncsis.2014.49.
Bei, L., Shah, C., Wang, H., Huang, W., Platanias, L. C., & Eklund, E. A. (2014). Regulation of CDX4 gene transcription by HoxA9, HoxA10, the Mll-Ell oncogene and Shp2 during leukemogenesis. Oncogenesis, 3e135. https://doi.org/10.1038/oncsis.2014.49
Bei, L, et al. "Regulation of CDX4 gene transcription by HoxA9, HoxA10, the Mll-Ell oncogene and Shp2 during leukemogenesis." Oncogenesis vol. 3 (2014): e135. doi: https://doi.org/10.1038/oncsis.2014.49
Bei L, Shah C, Wang H, Huang W, Platanias LC, Eklund EA. Regulation of CDX4 gene transcription by HoxA9, HoxA10, the Mll-Ell oncogene and Shp2 during leukemogenesis. Oncogenesis. 2014 Dec 22;3:e135. doi: 10.1038/oncsis.2014.49. PMID: 25531430; PMCID: PMC4275563.
Copy Download .nbib Format: NLM
Mnk kinase pathway: Cellular functions and biological outcomes.

World journal of biological chemistry

Joshi S, Platanias LC.
PMID: 25225600
World J Biol Chem. 2014 Aug 26;5(3):321-33. doi: 10.4331/wjbc.v5.i3.321.

The mitogen-activated protein kinase (MAPK) interacting protein kinases 1 and 2 (Mnk1 and Mnk2) play important roles in controlling signals involved in mRNA translation. In addition to the MAPKs (p38 or Erk), multiple studies suggest that the Mnk kinases...

Cite
Joshi S, Platanias LC. Mnk kinase pathway: Cellular functions and biological outcomes. World J Biol Chem. 2014;5(3):321-33doi: 10.4331/wjbc.v5.i3.321.
Joshi, S., & Platanias, L. C. (2014). Mnk kinase pathway: Cellular functions and biological outcomes. World journal of biological chemistry, 5(3), 321-33. https://doi.org/10.4331/wjbc.v5.i3.321
Joshi, Sonali, and Platanias, Leonidas C. "Mnk kinase pathway: Cellular functions and biological outcomes." World journal of biological chemistry vol. 5,3 (2014): 321-33. doi: https://doi.org/10.4331/wjbc.v5.i3.321
Joshi S, Platanias LC. Mnk kinase pathway: Cellular functions and biological outcomes. World J Biol Chem. 2014 Aug 26;5(3):321-33. doi: 10.4331/wjbc.v5.i3.321. PMID: 25225600; PMCID: PMC4160526.
Copy Download .nbib Format: NLM
Type I and II Interferons in the Anti-Tumor Immune Response.

Cancers

Fenton SE, Saleiro D, Platanias LC.
PMID: 33801234
Cancers (Basel). 2021 Mar 02;13(5). doi: 10.3390/cancers13051037.

The interferons (IFNs) are essential components of the immune response against infections and malignancies. IFNs are potent promoters of the anti-tumor response, but there is also evidence that feedback mechanisms regulated by IFNs negatively control immune responses to avoid...

Cite
Fenton SE, Saleiro D, Platanias LC. Type I and II Interferons in the Anti-Tumor Immune Response. Cancers (Basel). 2021;13(5)doi: 10.3390/cancers13051037.
Fenton, S. E., Saleiro, D., & Platanias, L. C. (2021). Type I and II Interferons in the Anti-Tumor Immune Response. Cancers, 13(5), . https://doi.org/10.3390/cancers13051037
Fenton, Sarah E, et al. "Type I and II Interferons in the Anti-Tumor Immune Response." Cancers vol. 13,5 (2021). doi: https://doi.org/10.3390/cancers13051037
Fenton SE, Saleiro D, Platanias LC. Type I and II Interferons in the Anti-Tumor Immune Response. Cancers (Basel). 2021 Mar 02;13(5). doi: 10.3390/cancers13051037. PMID: 33801234; PMCID: PMC7957896.
Copy Download .nbib Format: NLM
Schlafen 5 as a novel therapeutic target in pancreatic ductal adenocarcinoma.

Oncogene

Fischietti M, Eckerdt F, Blyth GT, Arslan AD, Mati WM, Oku CV, Perez RE, Lee-Chang C, Kosciuczuk EM, Saleiro D, Beauchamp EM, Lesniak MS, Verzella D, Sun L, Fish EN, Yang GY, Qiang W, Platanias LC.
PMID: 33846574
Oncogene. 2021 May;40(18):3273-3286. doi: 10.1038/s41388-021-01761-1. Epub 2021 Apr 12.

We provide evidence that a member of the human Schlafen (SLFN) family of proteins, SLFN5, is overexpressed in human pancreatic ductal adenocarcinoma (PDAC). Targeted deletion of SLFN5 results in decreased PDAC cell proliferation and suppresses PDAC tumorigenesis in in...

Cite
Fischietti M, Eckerdt F, Blyth GT, et al. Schlafen 5 as a novel therapeutic target in pancreatic ductal adenocarcinoma. Oncogene. 2021;40(18):3273-3286doi: 10.1038/s41388-021-01761-1.
Fischietti, M., Eckerdt, F., Blyth, G. T., Arslan, A. D., Mati, W. M., Oku, C. V., Perez, R. E., Lee-Chang, C., Kosciuczuk, E. M., Saleiro, D., Beauchamp, E. M., Lesniak, M. S., Verzella, D., Sun, L., Fish, E. N., Yang, G. Y., Qiang, W., & Platanias, L. C. (2021). Schlafen 5 as a novel therapeutic target in pancreatic ductal adenocarcinoma. Oncogene, 40(18), 3273-3286. https://doi.org/10.1038/s41388-021-01761-1
Fischietti, Mariafausta, et al. "Schlafen 5 as a novel therapeutic target in pancreatic ductal adenocarcinoma." Oncogene vol. 40,18 (2021): 3273-3286. doi: https://doi.org/10.1038/s41388-021-01761-1
Fischietti M, Eckerdt F, Blyth GT, Arslan AD, Mati WM, Oku CV, Perez RE, Lee-Chang C, Kosciuczuk EM, Saleiro D, Beauchamp EM, Lesniak MS, Verzella D, Sun L, Fish EN, Yang GY, Qiang W, Platanias LC. Schlafen 5 as a novel therapeutic target in pancreatic ductal adenocarcinoma. Oncogene. 2021 May;40(18):3273-3286. doi: 10.1038/s41388-021-01761-1. Epub 2021 Apr 12. PMID: 33846574; PMCID: PMC8106654.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 24 entries